- Home
- FFNW vs INBX Comparison
FFNW vs INBX Comparison
Compare FFNW & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFNW
- INBX
- Stock Information
- Founded
- FFNW 1923
- INBX 2010
- Country
- FFNW United States
- INBX United States
- Employees
- FFNW N/A
- INBX N/A
- Industry
- FFNW Banks
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- FFNW Finance
- INBX Health Care
- Exchange
- FFNW Nasdaq
- INBX Nasdaq
- Market Cap
- FFNW 197.8M
- INBX 198.2M
- IPO Year
- FFNW N/A
- INBX 2020
- Fundamental
- Price
- FFNW $22.64
- INBX $14.15
- Analyst Decision
- FFNW Hold
- INBX Hold
- Analyst Count
- FFNW 2
- INBX 1
- Target Price
- FFNW $22.75
- INBX N/A
- AVG Volume (30 Days)
- FFNW 37.3K
- INBX 94.2K
- Earning Date
- FFNW 04-29-2025
- INBX 05-08-2025
- Dividend Yield
- FFNW 0.57%
- INBX 5.75%
- EPS Growth
- FFNW N/A
- INBX N/A
- EPS
- FFNW 0.12
- INBX 119.38
- Revenue
- FFNW $37,609,000.00
- INBX $1,568,000.00
- Revenue This Year
- FFNW N/A
- INBX N/A
- Revenue Next Year
- FFNW $0.82
- INBX N/A
- P/E Ratio
- FFNW $194.00
- INBX $0.12
- Revenue Growth
- FFNW N/A
- INBX 19.24
- 52 Week Low
- FFNW $18.03
- INBX $10.80
- 52 Week High
- FFNW $23.50
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- FFNW 67.55
- INBX 57.87
- Support Level
- FFNW $19.14
- INBX $12.30
- Resistance Level
- FFNW $21.66
- INBX $13.85
- Average True Range (ATR)
- FFNW 0.54
- INBX 0.90
- MACD
- FFNW 0.02
- INBX 0.17
- Stochastic Oscillator
- FFNW 97.67
- INBX 68.42
About FFNW First Financial Northwest Inc.
First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.